Quince Therapeutics, Inc. - 8-K Filing
Quince Therapeutics acquired Orphai Therapeutics in a merger effective May 17, 2026, issuing approximately 3.25 million shares of common stock and 67 thousand shares of Series C Preferred Stock to HoldCo shareholders. Post-merger ownership shows former equityholders of Quince holding ~82.2% before additional financing and ~31.9% afterward; investors will hold ~61.2%. The transaction is structured as a tax-free reorganization. (Items: 5.03 of this Current Report on Form 8-K, which is incorporated into this Item 1, 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2, 7.01 of this Current Report on Form 8-K, including the information in the press releases attached as Exhibits 99)
Tickers: $QNCX